Inloggad som:
avslutad_InMIND - INCMOR 0208-301
Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.
avslutad_InMIND - INCMOR 0208-301
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF TAFASITAMAB PLUS LENALIDOMIDE IN ADDITION TO RITUXIMAB VERSUS LENALIDOMIDE IN ADDITION TO RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) GRADE 1-3A OR R/R MARGINAL ZONE LYMPHOMA (MZL)
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF TAFASITAMAB PLUS LENALIDOMIDE IN ADDITION TO RITUXIMAB VERSUS LENALIDOMIDE IN ADDITION TO RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) GRADE 1-3A OR R/R MARGINAL ZONE LYMPHOMA (MZL)
PLACEHOLDER
Mer information om studien för vårdgivare
Studien ändrades senast av: studysonia (2023-09-26)